The global CAR T-cell therapy market is poised for significant growth, with its size projected to increase from USD 4.6 billion in 2024 to USD 15.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 11.4% during this period. This expansion is driven by advances in innovative technology platforms, substantial funding, and encouraging clinical trial outcomes, positioning CAR T-cell therapy as a transformative approach in cancer treatment and beyond.
Market Growth Drivers
Cancer remains a leading cause of death worldwide, with the World Health Organization reporting 10 million cancer-related deaths in 2020 and an expected rise to 27.5 million new cases by 2040. Conventional treatments such as chemotherapy, radiation, and surgery often struggle to achieve lasting remission. CAR T-cell therapies offer a promising alternative by harnessing the patient’s immune system to specifically target and eradicate tumor cells with fewer side effects. This immunotherapy approach has revolutionized cancer treatment globally and continues to evolve with the discovery of novel molecular targets.
The CAR T-cell therapy market growth is further fueled by over 800 CAR T-cell therapy programs in clinical development, including approximately 300 targeting oncological disorders in early stages. Around 10 CAR T-cell therapies have been commercialized, with six approved in the US for hematological malignancies, targeting primarily CD19 and BCMA antigens. The increasing number of clinical trials—about 1,000 registered in the past eight years, with 60% actively recruiting—reflects robust research activity and investor confidence, supported by more than USD 32 billion in capital investments and over 10,000 patents filed or granted related to CAR T-cell therapies.
Market Segmentation
- Target Indications: The market covers a range of hematological cancers including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. Multiple myeloma currently holds the largest market share (~30%) and is expected to maintain dominance. Large B-cell lymphoma therapies are projected to grow at a CAGR of 14% during the forecast period.
- Target Antigens: CD19-targeting therapies dominate the market, accounting for more than 65% of the share, driven by successful products like Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel). Other antigens include BCMA, CD20, and CD19/CD22 combinations.
- Geographical Regions: North America leads the market with over 65% share, supported by accelerated regulatory approvals and high adoption rates despite the high cost of therapies. Asia-Pacific is the fastest-growing region with an expected CAGR of 21%, while Europe is projected to capture about 20% of the global market by 2030, aided by approvals such as NICE’s endorsement of Yescarta® for NHS provision in the UK.
- Key Drugs: The FDA-approved CAR T-cell therapies as of 2024 include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti. Many of these have received expanded indications since their initial approvals.
Challenges
The high cost and complex manufacturing processes of CAR T-cell therapies pose significant challenges. Manufacturing bottlenecks, such as shortages of viral vectors, have impacted supply and rollout, as seen with BMS’s Abecma® and Janssen’s phased launch of Carvykti®. These factors limit broader adoption, especially where reimbursement is unavailable. However, these issues may ease as the market matures and contract manufacturing organizations expand capacity.
Key Players and Competitive Landscape
Over 210 companies are actively developing CAR T-cell therapies for oncological and non-oncological indications. Leading industry players include Gilead Sciences (Kite Pharma), Bristol Myers Squibb, Novartis, Janssen, JW Therapeutics, Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, and others. Kite Pharma notably achieved FDA approval in early 2024 for an improved manufacturing process of Yescarta®, reducing turnaround times significantly.
The sector has witnessed more than 260 partnerships and collaborations to accelerate development, alongside substantial venture capital and public funding. This collaborative environment, combined with a strong pipeline and ongoing clinical trials, underscores the dynamic and rapidly evolving nature of the CAR T-cell therapy market.
Conclusion
The CAR T-cell therapy market is on a robust growth trajectory, driven by unmet medical needs in cancer treatment, technological innovation, and strong investment. While challenges related to manufacturing complexity and therapy costs remain, the expanding pipeline, increasing approvals, and geographic market expansion suggest that CAR T-cell therapies will become a cornerstone of personalized cancer treatment and potentially other disease areas by 2035.
---
This summary is based exclusively on the detailed analysis and data provided by the Roots Analysis report on the CAR T-cell therapy market, reflecting the current landscape, segmentation, growth drivers, challenges, and key industry players as of 2024-2025.
Thank you for reading Roots Analysis report. Kindly get in touch with Roots’ team to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
About Roots Analysis
Roots Analysis is a global leader in market research, competitive intelligence and consulting services across industries. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, and venture and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/